AB
APGE icon

Amalgamated Bank’s Apogee Therapeutics APGE Stock Holding History

Amalgamated Bank’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,210
Closed -$91K – 1693
2025
Q4 		$91K Buy
1,210
+149
+14% +$9.38K ﹤0.01% 1711
2025
Q3 		$42K Sell
1,061
-251
-19% -$9.58K ﹤0.01% 1890
2025
Q2 		$57K Hold
1,312
– – ﹤0.01% 1804
2025
Q1 		$49K Buy
1,312
+61
+5% +$2.36K ﹤0.01% 1798
2024
Q4 		$57K Hold
1,251
– – ﹤0.01% 1804
2024
Q3 		$73K Hold
1,251
– – ﹤0.01% 1756
2024
Q2 		$49K Sell
1,251
-137
-10% -$6.65K ﹤0.01% 1855
2024
Q1 		$92K Sell
1,388
-853
-38% -$37.2K ﹤0.01% 1740
2023
Q4 		$63K Sell
2,241
-220
-9% -$4.41K ﹤0.01% 2146
2023
Q3 		$52K Buy
+2,461
New +$54.2K ﹤0.01% 2234

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Amalgamated Bank's APGE Position: Q1 2026 in Review

Amalgamated Bank sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 1,210 shares — an estimated $91K sold.

Amalgamated Bank first reported a position in APGE in Q3 2023 and held it in 10 quarters. The position peaked at $92K in Q1 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Amalgamated Bank reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,210 Apogee Therapeutics shares in Q1 2026, an estimated $91K.
  • Amalgamated Bank first reported a position in Apogee Therapeutics in Q3 2023 and held it in 10 quarters.
  • Amalgamated Bank's Apogee Therapeutics position peaked at $92K in Q1 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.